Trademark: 86287682
Word
SAMIRNA
Status
Registered
Status Code
704
Status Date
Wednesday, October 5, 2022
Serial Number
86287682
Registration Number
5052167
Registration Date
Tuesday, October 4, 2016
Mark Type
4000
Filing Date
Wednesday, May 21, 2014
Published for Opposition
Tuesday, July 19, 2016

Trademark Owner History
BIONEER CORPORATION - Original Registrant

Classifications
5 Pharmaceutical preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Biological preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Medicated vaccines and serums for treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Microspheres containing pharmaceutical preparations, for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Preparations and substances for facilitating delivery of pharmaceutical preparations, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery system, namely, elixirs for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulations, namely, compositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression
1 Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analyses, other than for medical use, namely, chemicals for use in biotechnological product development; Chemicals for pharmaceutical purposes, namely, for use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicals, namely, biochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products
10 [ Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheres, namely, unilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies ]
42 Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality control, namely, quality control of target gene expression activity with siRNA; Biotechnology research

Trademark Events
Oct 5, 2022
Notice Of Acceptance Of Sec. 8 - E-Mailed
Oct 5, 2022
Registered - Partial Sec. 8 (6-Yr) Accepted
Oct 4, 2022
Case Assigned To Post Registration Paralegal
Apr 26, 2022
Teas Section 8 Received
Oct 4, 2021
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Oct 4, 2016
Registered-Principal Register
Jul 19, 2016
Official Gazette Publication Confirmation E-Mailed
Jul 19, 2016
Published For Opposition
Jun 29, 2016
Notification Of Notice Of Publication E-Mailed
Jun 15, 2016
Law Office Publication Review Completed
Jun 8, 2016
Approved For Pub - Principal Register
Jun 8, 2016
Examiner's Amendment Entered
Jun 8, 2016
Notification Of Examiners Amendment E-Mailed
Jun 8, 2016
Examiners Amendment E-Mailed
Jun 8, 2016
Examiners Amendment -Written
May 21, 2016
Teas/Email Correspondence Entered
May 20, 2016
Correspondence Received In Law Office
May 20, 2016
Teas Response To Office Action Received
Nov 23, 2015
Notification Of Priority Action E-Mailed
Nov 23, 2015
Priority Action E-Mailed
Nov 23, 2015
Priority Action Written
Nov 16, 2015
Data Modification Completed
Nov 16, 2015
Assigned To Lie
Nov 9, 2015
Assigned To Examiner
Oct 23, 2015
Teas/Email Correspondence Entered
Oct 23, 2015
Correspondence Received In Law Office
Oct 23, 2015
Teas Response To Suspension Inquiry Received
Aug 21, 2015
Notification Of Inquiry As To Suspension E-Mailed
Aug 21, 2015
Inquiry To Suspension E-Mailed
Aug 21, 2015
Suspension Inquiry Written
Feb 6, 2015
Notification Of Letter Of Suspension E-Mailed
Feb 6, 2015
Letter Of Suspension E-Mailed
Feb 6, 2015
Suspension Letter Written
Feb 5, 2015
Teas/Email Correspondence Entered
Feb 4, 2015
Correspondence Received In Law Office
Feb 4, 2015
Teas Response To Office Action Received
Aug 4, 2014
Notification Of Non-Final Action E-Mailed
Aug 4, 2014
Non-Final Action E-Mailed
Aug 4, 2014
Non-Final Action Written
Aug 4, 2014
Assigned To Examiner
Jun 4, 2014
New Application Office Supplied Data Entered In Tram
May 24, 2014
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24